FDA has approved rusfertide, a groundbreaking therapy that promises to spare patients with polycythemia vera (PV) repeated phlebotomies, the agency and officials from Takeda and P ...

China survey reveals what R/R mantle cell lymphoma patients and doctors value after BTK failure—overall survival tops trade-offs despite CRS risk. Despite advances in recent years, treatment choices ...

MINT randomized 238 patients to inebilizumab 300 mg IV vs placebo with a protocol-driven taper to prednisone ≤5 mg/day and ...

Transplant weight-loss access, a new dermatomyositis drug, mifepristone safety views, and racial gaps in cataract surgery and ...

T-cell therapy has transformed outcomes in several blood cancers, but its success is far from uniform. According to Kerry ...

The federal government's posture in Texas v Kennedy —a lawsuit over HHS's 2024 update to Section 504 of the Rehabilitation ...

A large, long-term real-world study found that biologic therapy for psoriasis is linked to a significantly lower risk of ...

The hypothalamus of an adult living with narcolepsy type 1 (NT1) measures smaller than that of a person without the disorder, ...

FDA approves brepocitinib, the first oral, targeted therapy for adult dermatomyositis, backed by phase 3 VALOR data. For the ...

Tirzepatide is now approved to lower cardiovascular death, heart attack, or stroke risk in adults with type 2 diabetes.

Children and young adults who were unvaccinated and infected with COVID-19 were at an increased risk of developing ...

County-level CRC mortality fell substantially since 2000, but some counties still had rates more than 13 times the Healthy ...